ReviewNeurology2023
Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist.
Review in Neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 4 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Association between blood neurofilament light chain levels and vascular cognitive impairment: a systematic review and meta-analysis.Frontiers in neuroscience · 2026Pooled it
- Prognostic biomarkers in ischemic stroke treated with mechanical thrombectomy: a systematic review.Arquivos de neuro-psiquiatria · 2025Pooled it
- Molecular Biomarkers for Early Detection of Alzheimer's Disease and the Complementary Role of Engineered Nanomaterials: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- SIMOA-based analysis of plasma NFL levels in MCI and AD patients: a systematic review and meta-analysis.BMC neurology · 2023Pooled it
- Measurement of Central Nervous System-Related Biomarkers in Plasma of Burn Patients.Shock (Augusta, Ga.) · 2026Article
- A Blood-Derived Factor Rescues ALS: Platelet Factor 4 Activates OPTN-Dependent Autophagy to Clear SOD1 Aggregates Independently of PINK1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cross-disease LC-MS/MS plasma proteomics identifies reproducible shared and disease-enriched biomarker signatures in neurodegenerative disorders.Acta neuropathologica communications · 2026Article
- Simoa and MSD platforms show analytical discordance but comparable diagnostic performance for GFAP, NF-L, and T-tau in adolescent concussion.Scientific reports · 2026Article
- Serum MAP1A as a Potential Biomarker for Autism Spectrum Disorder.Brain sciences · 2026Article
- Dementia in Progressive Supranuclear Palsy: A Narrative Review.Neurology and therapy · 2026Review
- Article
- Reduced plasma TIA-1: bridging established pathology and novel biomarker potential.Alzheimer's research & therapy · 2026Article
- Conserved Pathways, Divergent Outcomes: A Cross-Species Genomic Perspective on the Cancer-Neurodegeneration Paradox.International journal of molecular sciences · 2026Review
- Blood-based biomarkers for Alzheimer's disease diagnosis: a joint position paper from the Italian Societies of Neurology (SIN) and of Clinical Biochemistry and Clinical Molecular Biology - Laboratory Medicine(SIBioC) and from the Autonomous Association affiliated with SIN for dementia (SINdem).Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Artificial intelligence-based biomarkers for the diagnosis and treatment of neurological conditions: a narrative review.Molecular brain · 2026Review
- Classifying drug-related problems of neurodegenerative diseases in the physician-pharmacist joint clinic of neurology: an application of the PCNE method.BMC geriatrics · 2026Article
- Automated high-throughput quantification of plasma p-tau217 and APOE-ε4 for Alzheimer's disease diagnosis and cognitive decline in a memory cohort.Alzheimer's research & therapy · 2026Article
- Divergence of cortical neurophysiology across different neurodegenerative disorders compared to healthy ageing.Progress in neurobiology · 2026Article
- Leveraging machine learning and network biology approaches to predict brain gene expression from blood transcriptomes.GigaScience · 2026Article
- Cell death-associated genes as novel diagnostic biomarkers for autism spectrum disorder.Apoptosis : an international journal on programmed cell death · 2026Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
Blood-based biomarkers offer a major advance in the clinical evaluation of neurodegenerative diseases. Currently, research studies have reported robust assays of blood markers for the detection of amyloid and tau pathologies specific to Alzheimer disease (amyloid-β peptides, and p-tau) and nonspecific blood markers of neuronal (neurofilament light, β-synuclein, and ubiquitin-C-terminal-hydrolase-L1) and glial degeneration (glial fibrillary acidic protein) that can measure key pathophysiologic processes in several neurodegenerative diseases. In the near future, these markers may be used for screening, diagnosis, or disease and treatment response monitoring. Blood-based biomarkers for neurodegenerative diseases have been rapidly implemented in research, and they have the potential to enter clinical use soon in different clinical settings. In this review, we will describe the main developments and their potential implications for the general neurologist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.